ࡱ > 7 kP bjbjUU .v 7| 7| 8> Y l
8
D 4 o \ : " > $ % E - ^ s , , > e ) s s s T , p > s s s m r T @ > P 2
U R D ? 0 o ` 2 I * s , , , , WHY AMERICAN COMPANIES AND CONSUMERS
NEED TO ACT IMMEDIATELY TO SUPPORT THE ANH LAWSUIT
August 2003
Diverging views on the EU Directives
Manufacturers, suppliers, retailers, practitioners and consumers in Europe have received a very wide range of sometimes conflicting messages about the likely impact of the EU legislation (see Box 1 for summary). Information filtering across the Atlantic is even more inconsistent. With so much confusion, many companies are doing nothing.
Box 1: Summary of key EU Directives
The reality is that a clutch of EU legislation is making its way through the EU law-making pipeline covering the full spectrum of dietary supplements, including herbal products, so-called borderline products, fortified foods, sports nutrition. In addition new EU regulations on health claims have recently been proposed and these are more or less identical to those just proposed in the US. For many it is the combined effect of all the EU laws that is of greatest concern.
Fortunately, only one directive has so far been passed in to EU law and EU member country legislation, this being the Food Supplements Directive. There is therefore still considerable scope to amend and shape the other legislation, assuming European and international interests get behind the appropriate campaigns.
One of the reasons the Food Supplements Directive managed to scrape through the European Parliament is that major international and European trade associations advised their member companies that the directive was going to be generally beneficial for the industry and they should plan ahead to comply with it. In contrast, it has been consumer, retailer and practitioner groups, especially in the UK, Sweden and Ireland, that have consistently claimed that the legislation could be catastrophic for particular sectors.
Since the directives passage in to EU law, many of the leading companies and associations with interests in the innovative sector of the European dietary supplement industry have come together under the umbrella of the pan-European and international Alliance for Natural Health ( HYPERLINK "http://www.alliance-natural-health.org" www.alliance-natural-health.org).
A detailed look at the legislation suggests that the primary reason for discrepancies in view over the Food Supplement Directives impact is the difference in impact of the legislation on different sectors of the industry. Innovator suppliers and those who are dependent on their products will inevitably be hardest hit. Companies manufacturing or selling relatively low-dose, synthetic vitamins and inorganic minerals will actually be set to gain considerably from the legislation, benefiting from the single market conditions across the 15 EU member countries (soon to be enlarged to 25) set by the directive, its primary intended purpose.
But, for others, the loss of many food-state vitamins (e.g. mixed tocopherols, tocotrienols, natural carotenoids, methylcobalamin (a form of B12), a range of minerals such as sulphur, boron, vanadium, silicon and many chelated or plant-derived forms is of great concern. Since the Food Supplements Directive is incremental in its effects, with even the bans on nutrient forms not coming in to force until 1 August 2005, many detractors argue that future effects could cumulatively have catastrophic impacts on innovators, independent retailers and practitioners.
Food Supplements Directive: key concerns
In summary there are four primary concerns about the Food Supplements Directive. These are:
Limited range of nutrient forms allowed on the positive list (Annex I & II of FSD). The UK Food Standard Agency has determined that there are at least 270 ingredients (nutrient forms) that are presently used in the UK that are not included on the positive list. The National Association of Health Stores has in fact determined that this is an understatement, the real figure being in excess of 300 ingredients. These missing ingredients are included in some 5000 products just on the UK market. The Irish Association of Health Stores has determined that around 85% of vitamin/mineral products in Irish health stores contain one or more missing nutrient form and would require reformulation to comply with the directive. One of the greatest concerns of the Alliance for Natural Health (the leading pan-European group working to positively shape the legislation) is that many of the missing forms are food-forms that are more bio-available (and generally safer) than the synthetic or inorganic forms included on the positive list.
Difficulties and costs in submission of dossiers (Article 4.6) to allow derogated use of off-list nutrient forms. The key issue here is that most supplement companies are in fact formulation companies who buy in products from a limited number of raw ingredient manufacturers or producers. If these manufacturers choose not to put in dossiers, then the formulation company would not be able to use it. However, if one manufacturer submits (and has approved) a particular dossier, any formulator can use that ingredient (at least unti l 3 1 D e c e m b e r 2 0 0 9 ) . C o s t s f o r d o s s i e r s v a r y g r e a t l y a c c o r d i n g t o t h e a m o u n t a n d n a t u r e o f e x i s t i n g d a t a : b u t e s t i m a t e s v a r y f r o m 2 0 , 0 0 0 t o o v e r 3 0 0 , 0 0 0 , d e p e n d i n g o n t h e i n g r e d i e n t . I n a d d i t i o n , b e c a u s e t h e t i m e f r a m e s a r e l i m i t e d ( 1 2 J u l y 2 0 0 5 ) , t h e r e may not be sufficient time to generate all the data for some ingredients.
Reductions in Maximum Permitted Levels via unnecessarily low Upper Safe Levels (USLs), being developed by the SCF/EFSA without a procedure that allows open consultation with outside scientists or other experts. The Alliance for Natural Health Expert Committee has determined that some of the science being used by the SCF is flawed and it appears that it is being used in order to justify very low maximum levels of nutrients in food supplements (the consequence of this is that higher levels will still be regarded as drugs and can therefore only be administered by doctors as is currently the protocol in many of the countries with less permissive legislative regimes) (Article 5).
Future restrictions on nutrients other than vitamins and minerals as of 2007, such as amino acids, fatty aids, phytonutrients, enzymes, fibre, probiotics, etc. These restrictions could be brought in via a positive list system (Recitals 6 & 8, Article 4.8).
It seems that the intended purpose of the FSD is to protect the simplest, low-dose, food supplements, of the type typically sold in European supermarkets and pharmacies. The more specialist forms, particularly those using food-form nutrients will only be able to remain on the market after August 2005 if dossiers for their ingredients are submitted and accepted, with all the contingent difficulties.
For many companies there is simply not enough time to conduct the necessary safety studies, given that there has never been any incentive or reason to do this work for a large proportion of the food-form nutrients. For others the task is too expensive. Take for example, selenomethionine, the most common form of selenium found in foods and well known as a very important antioxidant mineral: this form of selenium was rejected by the European Food Safety Authority (EFSA, formerly the Scientific Committee on Food [SCF]) in 1999 because long-term safety studies had not been conducted. Instead, EFSA has allowed use of two inorganic forms of selenium (sodium selenate and sodium selenite) that are both more toxic and less beneficial as antioxidants. For many consumers this is very confusing, as they hear on one hand that we should increase our consumption of Brazil nuts which contain high doses of selenomethionine, yet the EU Commission does not approve on its positive list use of this safe form of selenium simply because the studies are not available. Are food manufacturers being asked to provide safety data on natural products? Who for, example, has been required to prove via clinical trials that fruits and vegetables are safe?
Legal challenge of the Food Supplements Directive
The ANH is working with its scientific Expert Committee, outhouse lawyers, public affairs and media specialists to either annul or positively shape key EU legislation set to otherwise severely impact the innovative supplement industry and its beneficiaries. Although there is plenty that can still be achieved by effective lobbying on the amendments to the Pharmaceuticals Directive and the Traditional Herbal Medicinal Products Directive, and ANH is hard at work on this, options are far fewer for the Food Supplements Directive.
There is still some room to influence the maximum permitted levels and positive lists for nutrient groups other than vitamins and minerals, but the directive has already passed into European law and gets its full teeth once the directive is implemented fully in EU member states 2 years after its transposition in to their laws, in August 2005.
So, on behalf of innovators and practitioners, the ANH is proposing to challenge the validity of this directive later this year, and is working on this case with its out-house lawyers who are among the most experienced European lawyers in the EU.
Challenging the directive would make no sense unless there were reasonable grounds and probabilities of success. The ANH has retained the only legal team to ever have overturned an EU Directive and after a detailed examination of the FSD, this team has given the ANH a green light to proceed (HYPERLINK "www.alliance-natural-health.org"www.alliance-natural-health.org; see Latest News, 8 August 2003). The case is being built on a number of grounds, but of particular importance are EU constitutional grounds which suggest that there is a real chance of annulling the directive.
In addition, it appears that the effects of the directive can be challenged on grounds of proportionality, based on the fact that that it will impact on certain sectors of the industry, notably those associated with innovative products, in a disproportionate manner. The challenge was mounted on 13th October 2003, but this is just the start of it. Legal, scientific and commercial experts remain hard at work on the case to strengthen the already solid foundations of the case. Interestingly, if the directive is annulled, all national laws reliant on the directive are likely to be invalid.
Dr Robert Verkerk, Executive Director of the ANH, said, the case will allow the real science of nutrients to be showcased to the Commission, to the Parliament and to the public generally. People will understand that supplementation of a good diet with high quality nutrients is a valid and effective way towards optimum health. There is no scientific rationale for accepting synthetic vitamins and a limited range of inorganic mineral forms while rejecting the plethora of naturally occurring vitamins and minerals. Winning the case will pave the way to a very bright future for the industry. We are not suggesting that there should be no directive at all, but the existing directive needs to be replaced with a re-worked version that allows for high quality, effective supplements across the whole of Europe. Its about harmonising to good standards, not bad ones.
It is now time for all manufacturers, suppliers, retailers and practitioners who believe their businesses are at risk to join the ANH campaign and support the legal challenge. Contact Henrietta Lee, the ANH Campaign Manager on info@alliance-natural-health.org or phone + 44 1252 371 275 to find out how you can join the campaign and be part of the ANHs rapidly expanding Support Base (see HYPERLINK "www.alliance-natural-health.org"www.alliance-natural-health.org). Support is needed NOW.
The other Directives
The two key EU directives that will regulate basic supplements will be the FSD (but only those containing ingredients on the positive list or for which dossiers have been approved) and the amended pharmaceutical directive (PD) (Directive 2001/83/EC), of which the traditional herbal medicinal products directive (THMPD) is a part. So if a product is not able to be controlled under the FSD, it will default to the PD. If it falls under the PD, it will either require a full drug license (with the very substantial data requirements and costs required for drug approvals) or, if appropriate, botanically-based products can be classified as medicinal herbs and benefit from a fast-track licensing scheme. This fast-track THMPD procedure requires that the applicant can demonstrate 30 years safe, traditional use is used in lieu of safety data (the major component of data required for market authorization as a drug).
The THMPD is passing through the European regulatory process now and one particularly contentious issue is the requirement in the EU Commissions proposed legislation for 15 years EU use, out of the total 30 years traditional use. The Alliance for Natural Health, along with several other organisations have tabled amendments and are campaigning to allow 30 years demonstrated safe use form anywhere in the world. They argue that limiting non-EU use will prevent interesting and beneficial herbs discovered in parts of the world with very strong herbal cultures (e.g. China, India, South East Asia, South Africa, South America) from being brought in to Europe and it will therefore strongly impact future innovation. The legislation would essentially have the effect of freeze-framing the industry in the early 1990s.
In addition to this, further directives are being prepared by the EU Commission on sports nutrition and fortified foods, and draft Health Claims Regulations were tabled in Brussels in July of this year.
Conclusion
The US dietary supplement industry has flourished in the face of what must be regarded relatively as very liberal laws. There are clearly steps being taken by the FDA and others to alter this, but it seems the industry together with its huge consumer support base has so far defended itself very well against unnecessarily restrictive legislation. The current US campaigns against Durbins Bill S722 is a good example of how a diverse range of interested parties can work together.
The US industry is without question the world leader in this field, and there is growing evidence that nutrients in dietary supplements may be used very successfully in the prevention or even treatment of diseases.
Owing to the trends towards global harmonization, and in particular increased pressure towards trans-Atlantic harmonization, the EU Directives have a direct influence on the shape of future US laws. In addition to this, many US companies have substantial and growing markets in Europe, which will, following enlargement in two years time, have a population of some 450 million people.
The Alliance for Natural Health developed initially as a diverse range of largely European interests who were not against legislation per se, but were concerned about legislation that would potentially kill off innovation in the future. It has now developed an increasingly strong support base across Europe as well as in the US. The joint international committee of the NNFA and AHPA in July unanimously put forward a motion that supported the ANHs legal action against the Food Supplements Directive. Some have gone as far as suggesting that the EU Directives are an even bigger threat to the US industry than the original proposal for DSHEA which was positively amended in 1994 following huge protests in Congress.
Time is of the essence and every company or individual with interests in the future of the dietary supplement industry, both in Europe and the US, should now very seriously consider whether they want to accept the Food Supplements Directive, or be part of the potentially ground-breaking challenge that could pave the way to a very bright future for the industry.
See ANH Expert Committee response to the EVM Report (November 2002); HYPERLINK "http://www.alliance-natural-health.org" www.alliance-natural-health.org (Documents / Food Supplements).
PAGE
PAGE 1
Amendments to the Pharmaceuticals Directive
This amends the existing Pharmaceuticals Directive (which governs the supply of drugs in the EU) by expanding the reach of the definition of a drug still further so as to enable re-classification of any supplement as a drug if it restores, corrects, or modifies physiological functions in the body. The proposed wider definition will cover practically all natural health products so that they are at grave risk of being re-classified as drugs.
It also extends jurisdiction of the Pharmaceuticals Directive so that it takes precedence over any product defined as a drug under the wide definition, even if that product was already regulated and permitted under other EU legislation (e.g. Food Supplements Directive, Traditional Herbal Medicinal Products Directive, Cosmetics Directive).
The Food Supplements Directive (passed in to EU member state laws by 31 July 2003)
Creates a safe harbour for food supplements (so that they are not classified as drugs) but limits the spectrum of nutrients, initially only vitamins and minerals, and could in the near future substantially limit the potency of nutrients in such products by reducing maximum permitted levels. It provides a severe restriction on freedom of speech by preventing publicity over inadequacies of a normal diet. By 2007 it will also apply to other nutrient groups such as fatty acids, amino acids, fibre, plant extracts, etc. The Directive has already passed into EU law and is now being transposed into the law of Member States, ANH began its challenge against the legality of this Directive in October 2003 (see HYPERLINK "http://www.alliance-natural-health.org" www.alliance-natural-health.org).
Traditional Herbal Medicinal Products Directive
This Directive, currently working its way through the EU legislature, creates a new class of traditional herbal medicinal products by providing for a simplified pharmaceutical registration (e.g. avoiding provision of safety and efficacy data) for specific traditionally used herbal medicinal products. But only if the products (including the same combination of herbal ingredients) comply with a range of conditions including having been in safe use for 30 years, 15 of which must be in the EU. This will mean that herbs from traditions outside of the EU, that have yet to be used in the EU, would not be eligible and could only be used following compliance with a full drugs regime.
For further information on the
Alliance for Natural Health:
Dr Robert Verkerk, Executive Director
e-mail: HYPERLINK "mailto:robv@alliance-natural-health.org" robv@alliance-natural-health.org
David Hinde, Legal Director
e-mail: HYPERLINK "mailto:david@alliance-natural-health.org" davidh@alliance-natural-health.org
Henrietta Lee, UK Campaign Manager
e-mail: HYPERLINK "mailto:info@alliance-natural-health.org" info@alliance-natural-health.org
Ingrid Franzon, Swedish Campaign Manager
e-mail: HYPERLINK "mailto:ingrid.franzon@alpha-plus.se" ingrid.franzon@alpha-plus.se
Web: HYPERLINK "http://www.alliance-natural-health.org" www.alliance-natural-health.org
Y g $ a ( @ I J ~ °~m~^NNNN; %j CJ OJ QJ U^J aJ mH sH CJ OJ QJ ]^J aJ mH sH B*OJ QJ ^J mH phB}d sH j CJ UaJ mH nH sH u CJ aJ mH sH 5CJ aJ mH sH 5CJ OJ QJ ^J aJ mH sH CJ OJ QJ ^J aJ mH sH "56CJ OJ QJ ^J aJ mH sH "5CJ OJ QJ \^J aJ mH sH "5CJ OJ QJ \^J aJ mH sH 2j 5CJ OJ QJ U\^J aJ mH nH sH u & Y Z f g
' ) 0 1 ' ( [ \
-D M
$-D M
a$ 8C C D jP ~ \ ! # 6 * L s F j$ k$ $ $ $ ֶpf 5CJ aJ mH sH !j 0J CJ OJ QJ U^J aJ 6CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ "56CJ OJ QJ ^J aJ mH sH CJ OJ QJ ^J aJ mH sH 0J CJ OJ QJ ^J aJ mH sH %j CJ OJ QJ U^J aJ mH sH +j CJ OJ QJ U^J aJ mH sH !\ K L j$ k$ $ $ & & (
( ) ) N+ O+ 7$ 8$ H$ h^h
& F
-D M
$ $ & & %& T& & & & ) ) ,* -* X* Y* Z* y* z* y, {, 2 2 2 2 2 2 2 2 Ͻ߮ߛ߅p`ߛJp +j
CJ OJ QJ U^J aJ mH sH CJ H*OJ QJ ^J aJ mH sH (>*B*CJ OJ QJ ^J aJ mH ph sH +j CJ OJ QJ U^J aJ mH sH %j CJ OJ QJ U^J aJ mH sH B*OJ QJ ^J mH phB}d sH "6CJ OJ QJ ]^J aJ mH sH CJ OJ QJ ]^J aJ mH sH CJ OJ QJ ^J aJ mH sH "5CJ OJ QJ \^J aJ mH sH O+ - - 1 1 2 2
3 3 6 6 9 9 : : : : : : : < < r= s= > > A A
-D M
7$ 8$ H$ 2 2
3 3 : : : V> > {? ? 5C 6C 7C 8C 9C :C C C C C C C C C C Ķҧ| qbqPbCbq 0J CJ OJ QJ ^J aJ #j CJ OJ QJ U^J aJ j CJ OJ QJ U^J aJ CJ OJ QJ ^J aJ
j 0J UB*mH phB}d sH j UmH nH u 6CJ OJ QJ ^J aJ mH sH CJ OJ QJ ^J aJ mH sH 56CJ OJ QJ ^J aJ 56CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ "56CJ OJ QJ ^J aJ mH sH 5CJ OJ QJ ^J aJ mH sH A 4C 5C 7C 8C C C D D D D D D D D ?D E E UG VG G J J $
& F a$ $h^ha$ $
& F a$ $a$ h]h &`#$
-D M
C C C D D D D
D D D
D D D D ?D XD qD D E E `E #F =F EF F F F VG uG G G H H H OH {H H H I qJ rJ J ƸƬƠƠƬƠƬƸƆƠƠƠw j CJ OJ QJ U^J aJ 6CJ OJ QJ ]^J aJ 5CJ OJ QJ ^J aJ CJ OJ QJ \^J aJ 6CJ OJ QJ ^J aJ 56CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ 0J OJ QJ ^J mH nH u0J OJ QJ ^J j 0J OJ QJ U^J 0J
j 0J U )J J J J J J J YK K L L L L 2L L M M M M N N ƸƬƠƒƆ vgUC "6CJ OJ QJ \^J aJ mHsH "5CJ OJ QJ \^J aJ mH sH CJ OJ QJ ^J aJ mH sH 6CJ OJ QJ ^J aJ mH sH CJ OJ QJ ]^J aJ 6CJ OJ QJ ]^J aJ 6CJ OJ QJ ^J aJ CJ OJ QJ \^J aJ 56CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ 0J CJ OJ QJ ^J aJ j CJ OJ QJ U^J aJ #j CJ OJ QJ U^J aJ J J M M M M M M N yN zN N N N O O O O P P cP dP fP gP hP iP
-D M
$h^ha$ $
& F
hh^ha$ N N UN VN WN wN xN zN N N N N N N N N N O 'O (O ]O ^O _O O O טmY醘@Y 1j1 6CJ OJ QJ U\^J aJ mH sH &0J 6CJ OJ QJ \^J aJ mH sH 1j& 6CJ OJ QJ U\^J aJ mH sH "6CJ OJ QJ \^J aJ mH sH "5CJ OJ QJ \^J aJ mH sH &0J 6CJ OJ QJ \^J aJ mHsH 1j 6CJ OJ QJ U\^J aJ mH sH "6CJ OJ QJ \^J aJ mHsH +j 6CJ OJ QJ U\^J aJ mH sH O O O O O O O O P P P P @P AP BP aP bP cP dP eP jP kP ƙƙr m d B*mH phB}d sH j4
U6CJ OJ QJ \^J aJ 1j/ 6CJ OJ QJ U\^J aJ mH sH &0J 6CJ OJ QJ \^J aJ mH sH 1j8 6CJ OJ QJ U\^J aJ mH sH +j 6CJ OJ QJ U\^J aJ mH sH "5CJ OJ QJ \^J aJ mH sH "6CJ OJ QJ \^J aJ mH sH iP jP kP
-D M
, 1h / =!"#$% D y K w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / D y K F y C:\Documents and Settings\damian\Local Settings\ingrid.franzon\Lokala instllningar\Temp\www.alliance-natural-health.org D y K F y C:\Documents and Settings\damian\Local Settings\ingrid.franzon\Lokala instllningar\Temp\www.alliance-natural-health.org D y K w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / D y K w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / D y K ! r o b v @ a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P m a i l t o : r o b v @ a l l i a n c e - n a t u r a l - h e a l t h . o r g D y K " d a v i d @ a l l i a n c e - n a t u r a l - h e a l t h . o r g y K R m a i l t o : d a v i d @ a l l i a n c e - n a t u r a l - h e a l t h . o r g D y K ! i n f o @ a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P m a i l t o : i n f o @ a l l i a n c e - n a t u r a l - h e a l t h . o r g D y K i n g r i d . f r a n z o n @ a l p h a - p l u s . s e y K H m a i l t o : i n g r i d . f r a n z o n @ a l p h a - p l u s . s e D y K w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g y K P h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / D d @$ \
C 8 A n a t u r a l _ h e a l t h y R M<0 x
8F M<0 JFIF H H Exif MM * b j( 1 r2 i H H Adobe Photoshop 7.0 2003:03:25 22:17:03 Р 0 ( &
r H H JFIF H H Adobe_CM Adobe d
T " ?
3 !1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw 5 !1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ? TI%)$IJI$RI$@}̡i J O cNI$$I)I$JTI%)$IJAʣ S"Lu;Zֵ=;ej:iQY}1̮̓?c \2^c jgakG_ղ~Uoٯc5ۙ` O|1ޣ?>*ce4H ^68ӻ s^9 6:#dQ9~k` }Lpj9y, I.WšjY[D ♟SK*5
mkM;nEs^[ksӢ:jekS}`nEx =q[-Yev;l~> 9RG4L=z3CtI$$I)I$JTI%)$IJ\֚:W~m 'Bo^w Vu_E X@g2Qy7WWpKS6 |/I9)NM5hx.:]f`K'cNO5l߰zlw MKO M~nMy PyثҺ %T&dDuV$)$IJI$SUٳ=ݢ ~=/kS {6UVNʉc A{AhtjIO- jo f6GUO^UV}= Zr(75m[avF7mT_uU ]c A{AhtjUpqdWRƱX2S]MmkK$
Q jts2PH"+.m4\lT۾Ug#fFUq/"auڰ[70_fM7*[& Wd گ01zv>1ǸTC^#\S ; vӕ[mձ夹mp-{mvC ! iGQױRsxyI_<˞=_Z RTqzU 5f=0{ u.57-ic ZHqw 4?c^wK+k{cۿr j Dhuy||DP:GD?-1 j -4
Ib<2k湅ŏ{}C:(7z]?&̆f43y5X"$G..즳 <9>趋܊7>}?GE,~2(ɽ>7~S/,M#{ NKӳӳm o_=>}y4]Ծ[^FV>;cfUޕY}uliTm]ؙV,yԾ鶺rp}fcэkɻv> ^ ODIRc7^K ms[EE/oY)Z;Ԕ TI%)T>~~.
fU!xW_]u]ͬ[wc^E_V
9x¾l֪C]c]}wSu.~ ,i$
w? EY :U}8 SkMv?Fjſi 5_ᑃ3vZ\rnw5?&Ǿʙd> Rݟ̭D;pc pj~Sc2-~/m5+7:k;:]g> zI&eY~SSd#k7㺪wYu$c ЀoSC#; leM s}>_Q݊>C>Ϳ ˎEsk^gR7e/ã;9P;QO]zI˞"eݏvVGPg37oV6Sg[ ~ήΥӝq}[{Z]M ۶k lbЮ$#wU*?g :_x7g{ -IOTʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$-Photoshop 3.0 8BIM% 8BIM
com.apple.print.PageFormat.PMHorizontalRes
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMHorizontalRes
7.200000000000000e+01
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PageFormat.PMOrientation
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMOrientation
1
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PageFormat.PMScaling
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMScaling
1.000000000000000e+00
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PageFormat.PMVerticalRes
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMVerticalRes
7.200000000000000e+01
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PageFormat.PMVerticalScaling
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMVerticalScaling
1.000000000000000e+00
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.subTicket.paper_info_ticket
com.apple.print.PageFormat.PMAdjustedPageRect
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMAdjustedPageRect
0.000000000000000e+00
0.000000000000000e+00
7.340000000000000e+02
5.760000000000000e+02
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PageFormat.PMAdjustedPaperRect
com.apple.print.ticket.creator
com.apple.printingmanager
com.apple.print.ticket.itemArray
com.apple.print.PageFormat.PMAdjustedPaperRect
-1.800000000000000e+01
-1.800000000000000e+01
7.740000000000000e+02
5.940000000000000e+02
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PaperInfo.PMPaperName
com.apple.print.ticket.creator
com.apple.print.pm.PostScript
com.apple.print.ticket.itemArray
com.apple.print.PaperInfo.PMPaperName
na-letter
com.apple.print.ticket.client
com.apple.print.pm.PostScript
com.apple.print.ticket.modDate
2000-07-28T22:57:04Z
com.apple.print.ticket.stateFlag
1
com.apple.print.PaperInfo.PMUnadjustedPageRect
com.apple.print.ticket.creator
com.apple.print.pm.PostScript
com.apple.print.ticket.itemArray
com.apple.print.PaperInfo.PMUnadjustedPageRect
0.000000000000000e+00
0.000000000000000e+00
7.340000000000000e+02
5.760000000000000e+02
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.PaperInfo.PMUnadjustedPaperRect
com.apple.print.ticket.creator
com.apple.print.pm.PostScript
com.apple.print.ticket.itemArray
com.apple.print.PaperInfo.PMUnadjustedPaperRect
-1.800000000000000e+01
-1.800000000000000e+01
7.740000000000000e+02
5.940000000000000e+02
com.apple.print.ticket.client
com.apple.printingmanager
com.apple.print.ticket.modDate
2003-03-25T22:16:25Z
com.apple.print.ticket.stateFlag
0
com.apple.print.ticket.APIVersion
00.20
com.apple.print.ticket.privateLock
com.apple.print.ticket.type
com.apple.print.PaperInfoTicket
com.apple.print.ticket.APIVersion
00.20
com.apple.print.ticket.privateLock
com.apple.print.ticket.type
com.apple.print.PageFormatTicket
8BIM x H H @Rg( H H ( d h 8BIM H H 8BIM& ? 8BIM
x8BIM 8BIM 8BIM
8BIM'
8BIM H /ff lff /ff 2 Z 5 - 8BIM p 8BIM 8BIM 8BIM @ @ 8BIM 8BIM I 0
U n t i t l e d - 1 0 null boundsObjc Rct1 Top long Leftlong Btomlong 0 Rghtlong slicesVlLs Objc slice sliceIDlong groupIDlong originenum ESliceOrigin
autoGenerated Typeenum
ESliceType Img boundsObjc Rct1 Top long Leftlong Btomlong 0 Rghtlong urlTEXT nullTEXT MsgeTEXT altTagTEXT cellTextIsHTMLbool cellTextTEXT horzAlignenum ESliceHorzAlign default vertAlignenum ESliceVertAlign default bgColorTypeenum ESliceBGColorType None topOutsetlong
leftOutsetlong bottomOutsetlong rightOutsetlong 8BIM 8BIM 8BIM
T ~
r JFIF H H Adobe_CM Adobe d
T " ?
3 !1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw 5 !1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ? TI%)$IJI$RI$@}̡i J O cNI$$I)I$JTI%)$IJAʣ S"Lu;Zֵ=;ej:iQY}1̮̓?c \2^c jgakG_ղ~Uoٯc5ۙ` O|1ޣ?>*ce4H ^68ӻ s^9 6:#dQ9~k` }Lpj9y, I.WšjY[D ♟SK*5
mkM;nEs^[ksӢ:jekS}`nEx =q[-Yev;l~> 9RG4L=z3CtI$$I)I$JTI%)$IJ\֚:W~m 'Bo^w Vu_E X@g2Qy7WWpKS6 |/I9)NM5hx.:]f`K'cNO5l߰zlw MKO M~nMy PyثҺ %T&dDuV$)$IJI$SUٳ=ݢ ~=/kS {6UVNʉc A{AhtjIO- jo f6GUO^UV}= Zr(75m[avF7mT_uU ]c A{AhtjUpqdWRƱX2S]MmkK$
Q jts2PH"+.m4\lT۾Ug#fFUq/"auڰ[70_fM7*[& Wd گ01zv>1ǸTC^#\S ; vӕ[mձ夹mp-{mvC ! iGQױRsxyI_<˞=_Z RTqzU 5f=0{ u.57-ic ZHqw 4?c^wK+k{cۿr j Dhuy||DP:GD?-1 j -4
Ib<2k湅ŏ{}C:(7z]?&̆f43y5X"$G..즳 <9>趋܊7>}?GE,~2(ɽ>7~S/,M#{ NKӳӳm o_=>}y4]Ծ[^FV>;cfUޕY}uliTm]ؙV,yԾ鶺rp}fcэkɻv> ^ ODIRc7^K ms[EE/oY)Z;Ԕ TI%)T>~~.
fU!xW_]u]ͬ[wc^E_V
9x¾l֪C]c]}wSu.~ ,i$
w? EY :U}8 SkMv?Fjſi 5_ᑃ3vZ\rnw5?&Ǿʙd> Rݟ̭D;pc pj~Sc2-~/m5+7:k;:]g> zI&eY~SSd#k7㺪wYu$c ЀoSC#; leM s}>_Q݊>C>Ϳ ˎEsk^gR7e/ã;9P;QO]zI˞"eݏvVGPg37oV6Sg[ ~ήΥӝq}[{Z]M ۶k lbЮ$#wU*?g :_x7g{ -IOTʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$ꤗʩ$8BIM! U A d o b e P h o t o s h o p A d o b e P h o t o s h o p 7 . 0 8BIM Hhttp://ns.adobe.com/xap/1.0/
adobe:docid:photoshop:5449f341-60a1-11d7-9d6d-db3b23cd8a21
Adobe d@ 0 :
u!" 1A2# QBa$3Rqb%C&4r
5'S6DTsEF7Gc(UVWdte)8fu*9:HIJXYZghijvwxyz m!1 "AQ2aqB#Rb3 $Cr4%ScD&5T6Ed'
sFtUeuV7)(GWf8vgwHXhx9IYiy*:JZjz ? ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~chiX)&yX+Hb@ \2bRO :2 T IkCso
U|h4mzmz.b"꿅Vj^LV:!^j۫˕yaޚ2 :j1WM|_־ܯ`d3F WtVP{2ԕ}]Jqؼ_aˊjfۼhN𦢿io2t q158b(X-T1!I t"2{^u{{^u{{^u{{^u{{^u{{^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u#GGXY"" ,*'=$c@:,w/|nU Qr{w'LC <1j}N,QjI
/A[^ Xc.&3{{͗9E]3'p¾2h I Qn;pvJ4E4,ѫ
b]hUy1%w%B, ?+M&u(-aFHF O;k{ u*u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^Fwp`v25sx]uy\FP =mtSD,0{f&tBI5奄u}u 6݂(YOwʹ斚t7L%Xv߬:^K.LMPCQ$ՇefVaBGiS:7/x9 ofHqCa3C#^??Dël0cb6sT4X0>%bԏe_뫰j h g^5vç ֿgOοCV}TEE O!;*K1;vw'ېD =bͬ yaܱ~|?YAB}~H]bx ?c -]-u4U4u1$TGQMQ Tr<,Ke$`*0d"P~ԇ ʋ$N6=A#u{{^~qn fz'z)Wc`^Fi>A
yPZk Fa~{o&nZ #&K4Ep5tq~Kg9< x9:d&QqИwv짧vz.FUB+Il hOǎ3r_'ECo.O?~|8}R]p@2w
4<+n8cyԫu~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺUni#`C20^G;FvU`3&" u9e[a'dS[AH`FH ]ٷ Jr,5sb㙵=6 $ b.k{n7+=U >>}b;1]pyjh Z"
*_:e~{ߺF7Qv->lM-F,
Dd uK*D
//V˲ZКLj֟Z|1Ӕ \UrLmA ըc:36G~mjKpm#/5B$6x
ZG1l2/a߬yo,#F?/CΠf *^bn[laA$fax 0 u~W'/ͅXtd}*ԡ6[3٨ۧKƼ ͧh;N%7)W
/ϸM; H Wzc$l ] tv68~]G]9* 3T I)[A"IeH wD~5#?a %G?U(0G !zu{{^u{{^u{{^u{{^u{{^u{{^uߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~W'3 z=16[/M#-F۵Azi#e0n )Mevk< )Jf cC= _ݏp_móMt gGΟ5Z C
H$3<;ww%ݘff7$O$I9,K1=qu~{ߺ^ {/1TT*d01mɦ_D/,'@|O*8w]"nHYS]\w fbhZHqF= n,>+?!㨲تk1h誢$cea~l},Es W8hdPG?:-n`=82HA[{`>Sy|5xwD25,r*ȸS=\0U>GX9wkJ45'# G>Ԏ vϹFnc9JN|Pw
`+,&Wqyx:=>G Q/ pʲ `M (NӀC<^Hr OZc x+lyFuJj]_Z12{:.{{^u{{^u{{^u{{^u{{^u{{^u{{^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^t 덏qژ,n1"%WSPSu "T(ECX]`4z-7K}k7k/o9PƊ>du[|jWjBOW7ڤV,bThTpM/7+ۛc y X nw{{>.< UU @O>u{{^u{]]S㐤=&37ow",zmEOK_6r3 BW!}nZ.Z@Oi]{3=% gA#a|="\
M_]>XSve/ϓau5x+W %t#lu:6j54Y: Jx\. 7]{+ LSj?=|_2p)./甶=
яԍrI)+QIҵ7/ϋ_ x݃r:sGbDD
<"t]VvH\ʜ[}Q
1$!?CZ+}_!rEu@
JMr;5jH$?0 *YQ*&K 3 .~QͿ!A1O@{i K Yfq5DIu
vڂ9 c?7 ݡ;%eh־ Gԏ'ͮښLN?s˴%lAMwꪪeOAJ
tK$#g^!r (
I
R >I\(o
b p|cbN Fé{^u{{^u{{^u{{^u{{^u{{^uߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^uYoN)u]^&Ei$DVV;_B[nA+}mF︒:~lTG;MKɵ7ӆёTWu{{^u{ݱ;qa6ޢ#9J,>* KO[_:S|q+ϥ6 j-m O#QI gtr/u4͘~^dh /#Jl}wX#WFZj!HI VͬŎ8lbm+sJl#aQ_\W_5^:
o%Jc\5 GfȾks:u{{^u{_oL\˓ڙnrT枆vBd)2 )OݺmȬ>t9FȞ}evʺMJ
`ؘL3~f1j $Uru?S0M DkOaQ]ݫV 9wu{{^u{{^u{{^u{{^u{{^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u@?̻TOnm2bU@梬`Gp81rHFA{X z>̉-1-7 / :O{
96K: 꽽=C{ߺ^u~{ߺGbPڝ+*k1G٪YXi[ToT)hQJf"[Ck&)a+_+0?zz}~+\jTPxVKwoոT>g!̠f%S%T
|T4FBEw7
Yr>^unW;{^>gcbI B紽"u{{^u{>n w/ #Hb]"yւ1T 2bE䫃u,jDZ?4c/Y_r/-ƥ`1Q;D?`Jtfz ~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^uߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^uS?c^Ʀ\[h%E-H|qSa*UXk /u [}5-~߽ao(JH~@-zN{{^u{
9 7su.م5Pf+ VȜ߸ken[SR0sU+*>c ٣|(G(|_~㾡{{^u{{^uK 9[pxvEUay5
Wv4٤#u #'ܼPcGycԋu~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^t#[*6Z
]IÀ<&+!L|sNalUk1MI;'<.U6Z4Z hbOɏZA $E#<U8uu{{^1mɤMro-%FnmPJbɰ>M;Z|I+D}ƿ&4SoD4C|CˤϨ.},5g7@u w;xMNjD\:裢'{^uOQW{hڟpvC ;*s' Wf7TJ`HUH?<{ lG) :S>LJ\ǗyI#S C [u~{ߺ^u~{ߺ^33v}Lg{]5SFc&C;&#rLlBcNCٛw ft_Ӵͩ5
ԓW.70sm llȞCM};<7d/y/ju~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~W {/X:Q6]#}L1TE4Ǣagu~{ߺ^u~{ߺY+* j稨(`i` 3 *).M $ ^:G RI O
~> .A%6ޒ "3,mYXjeLW. WI}|<#N h?E5 /w(?{\$Ӷ:F Yr0GFé{^u{{^u{{^u{{^u{{^u{{^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~cja()! YaTKI"R *`
B:*:PAg>\T
9
<}˲*&1O. ߮JAb
+/ܿn~NI~5_ZPrr2\Dl߫)_]!X] a^{ߺC ǽ bwoYm
\~Ov'̣#`0ٽí
0Xu˶#r66R %whK/ 4ӾO·Mۿ -Ҽn]Ӕƙ N@)i~{o|n;5YebA@ 1߹xk ~H~]z!u{{^u @ O 9${|z_ 42[ h>2]͝=PH 5 Q77r$GQ&xiɯj}~b+x3,2?)|DjӦ}˝d^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^uߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺE7GA|BLogܛ&PSY ?Ko[/;:r
HZWԚw'qI}W)l٢+H`;$QOMa Z#$h)bvXVI#"0 *H"uIV04 uF_SmLOy}Slpu+56?bg6⢛N7 H*{rHw׃AfȧI;VszW&v~jx5ܲ|´ҽa~{ߺ^u~{ߺ^aKvlYhZxKmYG(HS ]ۥZm-'RHף=g7o£V&<وQz?vRK]˱bXՈOuP2 3r*Eӯ*{kBC!xg_ e'!{Kc뾔E
+'_j$u3u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^=sz ? 4?0 ݷ;? WkȼZdVU,&o}]wЕǰ?nڬKnύ 6^?olٕ~! k$T"FS^ӄ$us]սmҪwl ^Įyen\esJꩨ^m*壐 2E7QpOK~]{ߺ^u~{ߺ^uY0=>i ?0mwJe ]C۸#1}ۯ V,ъf; {M=: ~{ߺ^uA??ѯe'fm!ꪊĂ2j3bʑ\RU >{71[%,&^,?c窘 b?|{ToA: (껽C]
pלǚ(~혅S+q}Wxx)v8b4%5 x$9q|W7 KuZzB9:H{
*Ҟ)쏠^u~{ߺO8
yZl efRbFE5Do `>߷`䝸*TpK[Y&nYՙ_ݻ绿*39h)+]ZFK"ЏJ}G%]aaro >d?U-Gȅ=N yM[qc!?) 學o]o]}x}ykb-4jgw)=5 | =>U/?㰻\ p[gcpv fcte
NɌ0殲$}.pz>|%>Smo_'ϩ{v {7? `wǽm g`lԙjh#ymE_QMJqӯo _ Ԉ
C$Z!M4^` W_Fn
̯QO ٘nM w `&ʎnx\}>vv5CTTgVҋc_Fν'zvO)]/@Aӵ}mű7b?Kc)(7~ E2X´_UU z;}7iS뛤-m,{Wu涖 snLv(ìtS
I BQï;o~? "7 I=&[nu]g+S49N8V+@jX]t!)Z j>
|H֟ISYջ?bF۱=u;{=Up.O$u:HRf5tg 0< {vd|L79 5zoPo]Ե{zd8.=EKEMv4V&1U3%4,P!Ze
WI_̇ ]!_,N+wdNi[#zlfW8L`嚝GYLBh uc%ghĬ>QvF9 oISm,b(rջyk(@
*iæN\Wwuf̘9->
PF ʱ\6 C7{tT ~G$y^捃p٧ 4X (oT=jӚc+Qˏa25 Ly uL@
YO)O Mo:6* 2{;K\쎧 :zeo|MS
~EoPl:
˜r6ףh(*p"Jz)[vGMKG?_
GCs4<;KAl >$ΰW@yp;j6۸pOsy
{8j!&z?'b}}SNmn`乓8N?]xg]]}_;(#I EeoY %q&K)2 Je#V۵EQzFOf'ivmmt(M1'u{{^u{{^u{{^u{{^u{{^u{{^u{ߺ^u~ )o A|ۓ
~z}O$71 IU5RKP#fKh[ר>=|'Cv> MiͫFn Ű25[S
GAǎJ֎Y#]Z%tc_ _joGGsO ¯V: }?~#:-t 7̏x Q09~8;K0[9gcxrnuQNp12<~@_o= p| #_@?Y3 L c7bJm ~[~2ۘ~ڲunRZ'ʝ呔oUN|7^t5ћ@|ڛ wаi+kUPEJ-J@ I^σ>LXo̦`ڍAڿ?/fa(hs.ݬ9($ˏXZCOF1gG? ~SKX
%]븓Oɽ[,oݷr1cq{ #SѺO%%=ul,2Z,H+ՔTQ _vi|# 1쮬oL^Qc1i2Y|>\}=2KQ]]ZXVz&(%ǽz@hN[yܽ;:3
W6m* d5t^ Ͳ+R# TRzJGDWRiǪ ŀmu }GG}9gK <7-FbQ#T-=AX Wq : UR 3 .ñ"s ~=? J:o~{ߺTG:=nq E$9 Eaw`ci
MO YBXv,X7XR-@OeǬPݾoHz 'kBUsjO$l& ,==B]})6ʬYwfol zj" l
{G)oޗan >N[n\ $۶m'OP͗ L9udg9ic}e7-bI;B%UcO>^:JXvj&~GڿacVaS^FIyuy8.v 0#?導.V.olʨc9*JMM:^yʴqij rl[FРmtQ 0ܾv}GF͏B^u{{^u{{^u{{^u{{^u{{^u{{^u{{^uߺ^u~A1nC
zfWRc5QK[C[K+,R#G$lU~S x]5f뫪 m]C&O/hU;^C>2;MFg`+
ӣ9m?~>q{:gtmjWQ-Qq5;(]ÊI{+)䥑Q\PijHBx1g_ɛ}'o?~r)]v+Ns+v\b)Kq8zLF fZJ8Y/ R1a~Wk`Su8L[Ʊa
HPo~ꤒ {~7rvWw}7WMˏ;ge6.^L qf)_cʄׁ 9zf6_6w[K-GVTYwYLm^=3_jf~~.iZZhRTGe^,H {+|Wv쾊ߖ`W1>w]jk29Mj)iF.>'" 7uBz1?Ə;yvY~Rb; 7gm.PMQKn_P䨢FY Gh+Z{U M6WtO'z%-;:ȮFc;zt6Ys|26-tFL|T. 9,}ּF
- 3mwNjMϿwvw3;o)ruy
ŹrlY-'EvS[gПu7mu.b !g/.];7rfV5?y-ҝxZ$Wӡߺ^ZYn麭}E6sn>FhaqyY
K$w-Y+I ){_YQQt'f8Pz{ RmJpYx *mI i@ ?OEPf7E?eSɗѤ ]PUb 1D2RTT]ha]ʓ] O# VG){M˼\ķۨ hq}M\:< ` yԩï{^u{{^u{{^u{{^u{{^u{{^u{{^u{{^u{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺAg[SO=gp{7)[ )][hޝɖyZz()=#ߺ$ҧOߺ^)jxfzIީ"$jj 5
F&=Drik6V&`H4?#ƇЃUtr\4> "Y۫u~{ߺ^u~{ߺ^u~W읋W ڛ
;
&2hsi*Y1I6>jw;gkKʂEH`eU * #{{ڹۑ% R 5!$UI#a>^ {}H/~G,9]rK +6! Gk]y}3k+e9=ŕ:9+2liK!S-euumN;nQUWU;JřؒI3Yey{ 15$$z=딮nfi.$c$rI܋* fWGFWё%8nJS{! TPz0#kMgD;Fk,rj:V%$Nqe ^_ng]m:Sg9k0jI'h5 RDД ݗw6m*x 2?P=M\ѳY65J2ԣFFqQFt {x*-~M&gsEZ1ᶙɗ5lS,3ʥ#[]oK]yT3֚cj5ZҚ{`T]Ζ<ǹm1X鶽IH#馎*z*tHr'Okc2 g!<@r? d?{ gd|u}iWn> ~7pJƯ]: Zm..e1.-
_ʙY)|Z-~_Z9i 4, m>bͬ~N Z+PR81<̜c^rI& WPZ
$F~ ]?'
3*L ttbMGf
G+/oQ2p7} i+?
JTWC^>~tc^` #ұwGCSEm}]GSG}Ԙdkm\!E%m5"Yz}灌OW J#/" { %scY2jj&pw)s˯yl.]|(љuB^hjǫAξ=S;k;ۙksy ՛WhciEQ(1ԫkaY=nv۸oy/',$`T QW| V[l/۟0˸wY]J I
Rc2[?aoߛ;4;(sM5ZK . y51?amjpi‹,@ЦU=}7]bgݷ n&K!b/*>+܋z 1=s )fwhkVV25ښ#UiiH<➦qGGCG,zyV->(b9˚-`,o+hAnjfaW5r@:UT) 7<ogs#wu)&BB `mg wt &wfonr٪
LJV4;¹ 2Dc:W *K{Yr a{c{ 4N Τ0u"kCԉ{U[R7dEuifÀE05c=
_!sm;;-=?ENTY,ףc 1hY ^cwp fX!SX' WQ+P o9wdł4gvYB[Z5 v~:lH||FO9 Δ3Wa ZBE犲f3yyg\l\rː"V0"-u|*
~ɤ yBOB?Bh;k?nCFٚX*UPӪ9*6H]t[" rW2o1m۪iM *T+
,+B8Kcqs
i k*IQRq 2 ?དs< 5 SܿxL? VX}Փ n?] SޏOCGg6称6~[oky /.^cnIwr,U '۹iqt|~D)*eJFN* ] l=W{/o}ǿ Kmie?ⱻ'Zo̅D,D8> [M$qБ ^f 5zgCWc{
kMm&/ml^U"'09횸>,R䝲;{iy`R{n:M͉G9TKYv~eLO;g&m{I2\z=$7ּUSooSp 9<~N}Vb!։i 1X؍QxV 665- ?7%sŦyYum{鞵n0S|>Kj >?t+Wظ*Jj}˚Rujĕ WTԊ, ^ʟKIs ]zg ./_&r*݇x{qAy~4 s]qG[-Ro \ecn 1 i_;*=;2Z]RX76&iJ=6W%wqa+uM:b: D X/tbo`q_[cw߲{F p Re}8N6h㲴0T w9#FE/ 7~+u K ݾ]u3ga wòcfV6ƤguYbtTddCe3I( 9>_zJ 쾱wɹis c7-9XоA(:͋|wO;V=c#{nd7ϵژ3̆ڬ;vT'|O T2U52ӣ6$V=
c? pv [4[~UoaLs(o$e bgTL*jiVzkSLua W- \HwƦ|cm`9m״ ; "zz1 5
IG")=_Ͽt^u~{ߺ_ߺ^u~{ߺ^u~{ߺ^u~T\&7r|Sf/# ς@*Q99%YX5=RA("!8"UeM=G?#ǯr-`;-nST! 䃨3ة],9oLݩZֽ 齿mCq;E ZVXb1Tϐ(u."%:(a!۲Vtp<ُc q4 K1lܵg 4ZԳDAVcA@D h _ݍ/^ ?o:mϰ_r}5ZjК~]F{( ~Zkoukwqc
i+ 4Mؘdedh*#FeU#,wn/v34jqFEJ:{?0sxDn"F []XSF$Tyj
z AڿOr $my 7S2 ʹ i';η F ^ U QDZ K = #n/ #,w_M㧪V(; C 1Q $mzU{}Y߹KӪi(: B1 $mz U͟{?J} {/ ,/TOoCo } k վ/p vNyʑzM͓09o ? Ujf삿ۑ6P YB:;]J]nQ2cyw L[Oo6gpZ9xQL3Y=?nco{͓`anHSԎ E|3yM;7TE%=H@|נ e _8 f{wq _N/7Gթ:zud t۷zO { gl տ>,uEWQbtq,a&S[Y$q*yJd輦Չh}uo*. `랽\.Σg7N"7re~%*\tZV[ןOaRz
mS~
|Q=uv9ݝi*.*}zn1T5O2"#ɐ"o Ϭn띍s a[gau쭟&'nm>'E RR#TwbYPIW?ͯW 3xk T3( ~>Ť;+lؚ
]nwVjbEAG\ 7f ~;jo=CNl|. v &ܫܛ_vy b 81_뭘hxE ۽ 5s|c?h%ا~ ۨ>s ǪG@' . }t 2 ۠ ó1ѬJ;ku?Xȱy*cnu2hYN_S$!#T ֤5vz~iT]5
ϖtˇf
Φ>=[3ANe5]o%}
ϧa5q/{鎽{{^uߺ^u~{ߺ^u~{ߺ^u~Uoʏ.?)yg 6 us=oo _~KܱuU# _ N/cq /Iݫ(svR6K +neHqC!_-FF9ibGSZZ\u*D~
5&|
W #=I
]'qmR0Ĩ5CCk ? _~ 7m 6i r?OJiOM4>T ~龏M:ti)馚i:^Mӟ7>=ť`w`;nIؘ}|x."EE+JcD7e]6{ @(:G j c 5~yڣ]^[IU$j uv,UٔTU}}iRK=FE jX
$ s&&Ӻ"
[ ju˰oF z ?oDcT|{R"fmz_Mx[+X~krr=5B?*?'F/}GkV
YAYKHXFTS
@/`M܉2"1Ŕ:.#2\ * lJ^WcoLV>Bỳ?tQQ
lt"OXZ EM7ݾ7 PHņӏνcߵL{ӴE.mfE'Q= H
ze _8 f{2_\y/kG Wӣr {m =0 T}Zc{^VOWGw w |?Oz==~ζ, d T84#6ܛ;cw6W+_5}cW$RҢEW-L HHUk ng.dCG d?oߺbo[GU]~tGO-LGZ\}v2DTTK#}# nrmIEWMN !2Kd&-' %|Nbqk/ۤ)|tO GE _| X_o֞1?+߁ 0 >_[½:u{{^ߺ^u~{ߺ^u~{ߺ^u~V=3~3&Y Xిo2S Q͏x)dY "i˙/9ەಙcѩV'S @Hzi.{][|-r$nѥ&buV&Pg(&6~V؛d O[G{/)O>; '54zu#eŅﭲ s!]hɨ
y%Ӻmֿ{mſqO7P -JP"G\{ۣ{{_?"UZsaއlI 49 b r9aIA
+Y+yڷ\G pA 8+Z
s_* |Y.-ޠ* T k E eg??i iºT>Wѫ1տv [^ M}5xz /
N4b`2 VzGB-Io=S飝,FKl9bwmPs 4pԮ2Qu ͵s<{pF:=c0o
zꬌYXVVee7HOݗ7/Vl:T8 bVYX&i2U*2UIO yd25[ӷ9E+JJԀJҽ _mja[pKc]DBHHfD [(n~Mؒm&}i&jkYl%DI@
bB MCvۑhLԮd 5=yk'3k65e#ǓE㢼tD;;{'K2 Ef딍 #=ls0▖\#3TR&H. w^M^fUTZ+9~vT|RZ{n:dG=TɊi?jq aVXӚ<qJ6 yuzq [+OW *|דt). {Қ*
鯖碣~Vv'l 9\6~gvL~O 5: Hk5Xei* Yݪ]&!K m!}d{$F8ƥWVZ`Ԓ6:Õ}-i71tTjh 5bXlune4.dUQa5UZ̄ t4hy"$B- YkF@%J 2Oʕ"y7K{w{UK9c 4 kZMwx
ӂmﰹen -E]i~hc=hX]X-9[k_Uf Aw"vAv6Y kq+
EATdx m .F ]uTUR̡ᩥT<4sDX~A*tIA ;8He@:AA 0O/=߹YN ϑ,GMNǏWb4t ԊYr1@ 67_^mZVbm%\Z qqӵɺr_BT NfW͡@'K @|-Bp=+*w|I9
щl>i)CS ,=/SUE>%T{}>FN P̣touE8iPB|QBgE8!Χ3 7U-VG*䷎C;{7rcfjG/[PVK"FBȅr&ѽӺMJ T[C;I=49=ֆ Yʹs}rꙑ7Ιh AP+Щbo}7ugwum*mS\5uD
XiitTKߛ/ynm).ʌʀL`PMHz?i/y=[Hn"2:F쑁pKIb(xue>ަ{n?Q}ݿ ~ ^>Ϙ{s䶧Quɏt]-Yk[7R`2:iji㨫6po Ƨ˫a:pٜ}v#1eqY:J 3%A
TqUQWQUDG"`#ߺl= >ֺ_ {n ȘmY 5>VlSVM1K]yW5 ?[$v }竷"
'gnm05E֛7on,ECF % !45 zϨfMSӼ~v /} z߱e6B lٺnujZZL/3}2+"Q$A-
h[/n]7wl}Nj]7evyn Lb}HD+J_uDɓ^\l˟F[q>6V tm
߄ѶxAOgZ, +CP9!he[嚞 ?~j/S7~9ތڝ=nu>EBK-}5GEQY pk
筪=zu{{^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^u~{ߺ^
i 8 @ 8 N o r m a l CJ _HaJ mH sH tH H H H e a d i n g 8 $d @& 5CJ OJ QJ \^J < A@ < D e f a u l t P a r a g r a p h F o n t 6 @ 6
F o o t n o t e T e x t CJ aJ 8 &@ 8 F o o t n o t e R e f e r e n c e H* . U@ . H y p e r l i n k >*B*ph , @ ", F o o t e r
! & )@ 1& P a g e N u m b e r , B, H e a d e r
! kK S V W X kK
S V W X [ kK v & Y Z f g
' ) 0 1 ' ( [
\
K L j k ! ! #
# $ $ N& O& ( ( , , - -
. . 1 1 4 4 5 5 5 5 5 5 5 7 7 r8 s8 9 9 < < 4> 5> 7> 8> > > ? ? ? ? ? ?? @ @ UB VB B E E E H H H H H H I yI zI I I I J J J J K K cK dK fK lK 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 @ 0
0 @ 0 @ 0 @ 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ~ $ 2 C J N O kP , / 1 3 5 6 8 9 \ O+ A J iP kP - 0 2 4 7 : jP . I ,% Y% y% - - - kK XXX ! !G } X`
E
f
M n 0 P [ XXXXXX 8 @ (
b
C " ` "
c R p . T T T T " `
t
s * " `
B
S ? 5> kK & - t@
: ! T@ M M L T I j u w
i w # + 7 ? & X% Y% + + e- j- - - ; ; 8> > > ? ?
? ? ? I I WI wI iK lK 1 F I $ $ X% Y% &
& - - i/ w/ / / 8> :> > > > ? ?
? ? ? E E I xI I I J J J J iK lK 3 3 3 3 3 3 3 3 3 3 3 % & A X I X% Y% g' ' ' ' ' ' ' ,( - - - - 5 5 5> 6> 7> 8> > > > ? ? ? D D D D E *E 4E ? G H yI lK aJ @ ; ( kK @ 4 @ U n k n o w n G z T i m e s N e w R o m a n 5 S y m b o l 3& z A r i a l " 1 h CzCzxf M3 m B 4 p ! 0 ?
> 3q H $ W H Y A M E R I C A N C O M P A N I E S A N D C O N S U M E R S
D a m i a n W a t s o n
D a m i a n W a t s o n Oh +'0 8 D
` l x
% WHY AMERICAN COMPANIES AND CONSUMERS ft HY Damian Watson OM ami ami Normal.dot o Damian Watson OM 2 mi Microsoft Word 9.0 I@ F# @ .l@ R껓@ R껓 M3 ՜. +,D ՜. +,P h p |
b m ?
% WHY AMERICAN COMPANIES AND CONSUMERS Title @ _PID_HLINKS _AdHocReviewCycleID _EmailSubject
_AuthorEmail _AuthorEmailDisplayName A B y C : \ D o c u m e n t s a n d S e t t i n g s \ d a m i a n \ L o c a l S e t t i n g s \ i n g r i d . f r a n z o n \ L o k a l a i n s t l l n i n g a r \ T e m p \ w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g y C : \ D o c u m e n t s a n d S e t t i n g s \ d a m i a n \ L o c a l S e t t i n g s \ i n g r i d . f r a n z o n \ L o k a l a i n s t l l n i n g a r \ T e m p \ w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g { 8 ( h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / { 8 ( h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / { 8 ( h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / z ] $ m a i l t o : i n g r i d . f r a n z o n @ a l p h a - p l u s . s e ? ( m a i l t o : i n f o @ a l l i a n c e - n a t u r a l - h e a l t h . o r g ) ) m a i l t o : d a v i d @ a l l i a n c e - n a t u r a l - h e a l t h . o r g ' ( m a i l t o : r o b v @ a l l i a n c e - n a t u r a l - h e a l t h . o r g { 8 ( h t t p : / / w w w . a l l i a n c e - n a t u r a l - h e a l t h . o r g / y K dP n a t u r a l _ h e a l t h y +>6 New article!! sp ! robv@alliance-natural-health.org ber Dr Robert Verkerk ra
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~ R o o t E n t r y F S D a t a
< 1 T a b l e W o r d D o c u m e n t .v S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8 C o m p O b j j O b j e c t P o o l SS
F Microsoft Word Document
MSWordDoc Word.Document.8 9q